drugset / Trial / NCT06310967
A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.
Timeline
- Start
- 2024-11-12
- Primary completion
- 2026-07
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IG3018 | Unknown | 0.25 g | Oral |
| Subject | IG3018 | Unknown | 0.5 g | Oral |
| Subject | IG3018 | Unknown | 1 g | Oral |